Suppr超能文献

采用实验设计方法评估吸入用抗生素/佐剂干粉联合制剂的可行性。

Feasibility of an inhaled antibiotic/adjuvant dry powder combination using an experimental design approach.

机构信息

Aix Marseille Univ, INSERM, SSA, MCT, 13385 Marseille, France.

Aix Marseille Univ, IRD, APHM, MEPHI, IHU Méditerranée Infection, Faculté de Médecine et de Pharmacie, 13385 Marseille, France.

出版信息

Int J Pharm. 2021 Apr 15;599:120414. doi: 10.1016/j.ijpharm.2021.120414. Epub 2021 Feb 27.

Abstract

The global increase of multidrug resistant bacteria and the lack of new classes of antibiotic especially those targeting Gram-negative pathogens are leaving the clinicians disarmed to treat numerous bacterial infections. Recently, the design of adjuvants able to enhance antibiotics activities appears to be one of the most promising investigated solutions to circumvent this problem. In this context, we have recently identified a new polyamino-isoprenyl derivative NV716 able to potentiate, at a very low concentration the activity of doxycycline against resistant P. aeruginosa bacterial strains by increasing its intracellular concentration. In this study we will report an experimental protocol to optimize a dry powder for inhalation ensuring the simultaneous delivery of an antibiotic (doxycycline) and an adjuvant (the polyaminoisoprenyl derivative NV716 since aerosol therapy could allow a rapid drug administration and target the respiratory system by avoiding the first pass effect and minimizing undesirable systemic effects. Thus, an experimental design was carried out permitting to identify the influence of several factors on the aerosolization efficiency of our combination and allowing us to find the right composition and manufacture leading to the best optimization of the simultaneous delivery of the two compounds in the form of an inhalable powder. More precisely, the powders of the two active ingredients were prepared by freeze drying and their aerosolization was improved by the addition of carrier particles of lactose inhalation grade. Under these conditions, the best formulation was defined by combining the optimal factors leading to the best aerodynamic properties' values (the lowest MMAD (Mass Median Aerodynamic Diameter) and the highest FPF (Fraction of Fine Particles)) without even using sophisticated engineering techniques. Finally, our results suggest that these molecules could be successfully delivered at the requested concentration in the lungs and then able to decrease drug consumption as well as increase treatment efficacy.

摘要

全球多药耐药菌的增加以及缺乏新的抗生素类别,尤其是针对革兰氏阴性病原体的抗生素类别,使得临床医生在治疗许多细菌感染时束手无策。最近,设计能够增强抗生素活性的佐剂似乎是解决这个问题最有前途的方法之一。在这方面,我们最近发现了一种新的多氨基异戊二烯衍生物 NV716,它能够以非常低的浓度增强多西环素对耐药铜绿假单胞菌菌株的活性,方法是增加其细胞内浓度。在本研究中,我们将报告一个优化干粉吸入剂的实验方案,以确保同时输送抗生素(多西环素)和佐剂(多氨基异戊二烯衍生物 NV716),因为气溶胶治疗可以允许快速给药,并通过避免首过效应和最小化不良的全身作用来靶向呼吸系统。因此,进行了实验设计,以确定几个因素对我们的联合制剂气溶胶化效率的影响,并使我们能够找到合适的组成和制造方法,从而以可吸入粉末的形式实现两种化合物的最佳同时输送的优化。更确切地说,通过冷冻干燥制备两种活性成分的粉末,并通过添加乳糖吸入级载体颗粒来改善其气溶胶化。在这些条件下,通过组合最佳因素来定义最佳配方,这些因素导致最佳空气动力学特性值(最低 MMAD(质量中值空气动力学直径)和最高 FPF(细颗粒分数)),甚至无需使用复杂的工程技术。最后,我们的结果表明,这些分子可以成功地以所需的浓度递送到肺部,从而能够减少药物消耗并提高治疗效果。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验